Esperion Therapeutics (NASDAQ:ESPR) CFO Benjamin Halladay Sells 10,773 Shares

Esperion Therapeutics, Inc. (NASDAQ:ESPR) CFO Benjamin Halladay sold 10,773 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $3.15, for a total value of $33,934.95. Following the transaction, the chief financial officer owned 702,829 shares in the company, valued at $2,213,911.35. The trade was a 1.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Esperion Therapeutics Stock Down 0.6%

Shares of ESPR traded down $0.02 during midday trading on Thursday, reaching $3.15. 17,492,649 shares of the stock were exchanged, compared to its average volume of 9,162,250. Esperion Therapeutics, Inc. has a twelve month low of $0.95 and a twelve month high of $4.18. The company has a market cap of $811.72 million, a P/E ratio of -52.50, a PEG ratio of 2.57 and a beta of 1.07. The stock’s 50 day simple moving average is $2.75 and its 200 day simple moving average is $3.12.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.08). Esperion Therapeutics had a net margin of 0.12% and a negative return on equity of 0.14%. The business had revenue of $80.10 million during the quarter, compared to analyst estimates of $84.52 million.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ESPR shares. HC Wainwright cut Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 price target on the stock. in a research report on Friday, May 1st. Citizens Jmp cut Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Jefferies Financial Group downgraded Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. Wall Street Zen raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Finally, Needham & Company LLC cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. One investment analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Esperion Therapeutics has a consensus rating of “Hold” and an average price target of $5.54.

Hedge Funds Weigh In On Esperion Therapeutics

Large investors have recently modified their holdings of the business. Kestra Advisory Services LLC acquired a new position in shares of Esperion Therapeutics during the fourth quarter worth $35,000. KFG Wealth Management LLC bought a new position in Esperion Therapeutics during the 4th quarter worth approximately $37,000. Cary Street Partners Financial LLC acquired a new position in shares of Esperion Therapeutics in the 4th quarter worth approximately $38,000. Larson Financial Group LLC acquired a new stake in Esperion Therapeutics during the 4th quarter worth about $39,000. Finally, Captrust Financial Advisors bought a new stake in Esperion Therapeutics in the fourth quarter worth approximately $40,000. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.